TY - JOUR KW - Adolescent KW - Adult KW - Aged KW - Biopsy, Needle KW - Child KW - Clofazimine KW - Cohort Studies KW - Dose-Response Relationship, Drug KW - Drug Administration Schedule KW - Drug Therapy, Combination KW - Female KW - Follow-Up Studies KW - Guidelines as Topic KW - Humans KW - Immunohistochemistry KW - Leprostatic Agents KW - leprosy KW - Male KW - Middle Aged KW - Risk Assessment KW - Severity of Illness Index KW - Skin KW - Treatment Outcome KW - World Health Organization AU - Prasad P V S AU - Babu A AU - Kaviarasan P K AU - Viswanathan P AU - Tippoo R AB -
BACKGROUND: The World Health Organization recommends treatment regimens for paucibacillary (PB) and multibacillary (MB) leprosy, which differ in their duration and components. Hence accurate classification of the disease is required. To overcome difficulties in classification Uniform Multi Drug Therapy (U-MDT) has been recommended.
AIM: To evaluate the benefit of adding clofazimine to paucibacillary regimens in leprosy patients by measuring clinical and histological resolution.
METHODS: Forty-four paucibacillary patients were included in the study. Twenty-two patients were given MDT-PB regimen and the remaining MDT-MB regimen for six months . Skin biopsies were done before the commencement and at the end of treatment. Clinical and histological resolutions were measured according to the standard criteria a laid down. The results were analyzed using Fishers' test and Crammers' V test.
RESULTS: Clinical improvement was observed in 90.9% in the MB group as compared to 27.3% in the PB group. Regression in the nerve swelling was observed in 70% in the MB group and in 37.5% in the PB group while histological resolution was observed in 72.8% and 54.5% respectively.
CONCLUSIONS: Addition of clofazimine helps to resolve leprosy lesions both clinically and histologically, thus justifying the concept of Uniform MDT regimen for all patients.
BT - Indian journal of dermatology, venereology and leprology C1 - http://www.ncbi.nlm.nih.gov/pubmed/16394431?dopt=Abstract DA - 2005 Jul-Aug IS - 4 J2 - Indian J Dermatol Venereol Leprol LA - eng N2 -BACKGROUND: The World Health Organization recommends treatment regimens for paucibacillary (PB) and multibacillary (MB) leprosy, which differ in their duration and components. Hence accurate classification of the disease is required. To overcome difficulties in classification Uniform Multi Drug Therapy (U-MDT) has been recommended.
AIM: To evaluate the benefit of adding clofazimine to paucibacillary regimens in leprosy patients by measuring clinical and histological resolution.
METHODS: Forty-four paucibacillary patients were included in the study. Twenty-two patients were given MDT-PB regimen and the remaining MDT-MB regimen for six months . Skin biopsies were done before the commencement and at the end of treatment. Clinical and histological resolutions were measured according to the standard criteria a laid down. The results were analyzed using Fishers' test and Crammers' V test.
RESULTS: Clinical improvement was observed in 90.9% in the MB group as compared to 27.3% in the PB group. Regression in the nerve swelling was observed in 70% in the MB group and in 37.5% in the PB group while histological resolution was observed in 72.8% and 54.5% respectively.
CONCLUSIONS: Addition of clofazimine helps to resolve leprosy lesions both clinically and histologically, thus justifying the concept of Uniform MDT regimen for all patients.
PY - 2005 SP - 242 EP - 5 T2 - Indian journal of dermatology, venereology and leprology TI - MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment. UR - http://www.ijdvl.com/article.asp?issn=0378-6323;year=2005;volume=71;issue=4;spage=242;epage=245;aulast=Prasad VL - 71 SN - 0378-6323 ER -